Positive Quarterly, PIQ have achieved a lot recently & revenue of $540K is very encouraging. Plus $6 million raise just in the last week to SIs which is not included in these figures.
I really like the stop sign indicator of risk for progression for DKD and recommendations for frequency of ongoing screening. Drs are busy people and this will also overcome International language barriers as well for results. PIQ have made their IVD version of PromarkerD a convenient and simple to use blood test, which is really what you want to see. If things are complicated and the process difficult, the less likely it will be utilised, but this is not the case here and not dependent on EMR which may not be available in all countries covered by IP.
The pie charts showing the number of global diabetes diagnosis covered by IP is just massive. Now with progression/validation of PromarkerD with Big Pharma (J&J) & simplification of testing, I think we should be receiving more positive news soon.
GLTAH
PIQ Price at posting:
55.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)